Amplia Therapeutics Ltd (ASX:ATX)'s Dr John Lambert walks investors through the latest news on the company's AMP945 drug candidate, which just secured ethics clearance for a phase two trial in pancreatic cancer patients. Dr Lambert says the green light represented the company's last hurdle, and the trial is now free to proceed with recruitment. It looks like the first patient will be dosed in April or May in New South Wales.
Amplia free to proceed with phase two pancreatic cancer trial
